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both regulatory agencies and all concerned. 
The availability of drugs, especially antibiot-
ics in open markets have led to indiscrimi-
nate use and may contribute to high inci-
dence of antibiotic resistance strains (Lester, 
1990). Nigeria imports a large proportion of 
its pharmaceuticals from different coun-
tries.This has led to indiscriminate dumping 
of sub-standard products in the Nigerian 
market. Lagos drug market is one of the larg-
est open drug markets in the country and 
served as the major source of drugs within 
the state and its neighboring environs includ-
ing some West African coun-
tries.Ciprofloxacin is synthetic fluorinated 
ABSTRACT 
The antimicrobial activity of five brands (A, B, C, D and E) of ciprofloxacin hydrochloride tablets com-
monly sold in Lagos Nigeria, were compared and assessed against susceptible clinical isolates 
(Staphylococcus aureus, Escherichia coli and Salmonella enterica serotypetyphi). Susceptibility test, 
minimum inhibitory concentration test and the bactericidal activity were determined. All sampled 
brands were within their shelf life. Most (60%) of the sampled brands were made in India while the 
remaining 40% were made in Nigeria. All the brands complied with the official specification in British 
Pharmacopeia (BP) for uniformity of weight as they show less than 5% deviation in weight. The mean 
antibacterial activities of the brands at 25µg/ml were found to be within the range of 38.0mm to 
42.2mm zone of inhibition while the MICs range between 0.012µg/ml to 1.5µg/ml. 
All the sampled brands were effective against all the test organisms to varying degree with brands A 
and E been more potent while brand D was the least effective. The order of MICs (decreasing order of 
potency) was D>B>C>A>E for Staphylococcus aureus and D>C>B>E>A for Escherichia coli while that 
of Salmonella enterica serotypeTyphiwas D>B>C>A>E. The bactericidal activity of each ciprofloxacin 
brand D and E are concentration-dependent; with brand E more active at all tested concentrations. 
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INTRODUCTION 
The introduction of generic drug product 
from multiple sources into the health care 
delivery system of many developing coun-
tries was aimed at improving the overall 
healthcare delivery systems in such coun-
tries. However, this has been accompanied 
by a variety of problems of which the most 
critical is the widespread distribution of fake 
and substandard drug products. There is 
growing trade in sub-standard and counter-
feit drugs including antibiotics around the 
world (Masland and Marshall, 1990). The 
prevalence of such substandard drugs in the 
Nigerian markets has been worrisome to 
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 quinolone that is indicated in infections of 
the urinary, gastrointestinal and respiratory 
tracts, tissue infections, gonorrhea and sep-
ticemia caused by sensitive organisms
(Solomkin, et al. 2010). It is effective in 
chronic Gram – negative infections such as 
osteomyelitis, recurrent cholangitis and 
acute exacerbations of pseudomonas infec-
tion as in cystic fibrosis (Bennett and 
Brown, 2003). It is suitable for the treat-
ment of bacterial keratitis, lower respiratory 
tract infections especially of Gram – nega-
tive etiology (Lode etal., 1994). Ciprofloxa-
cin is also widely used for several disease 
conditions and it is readily available in dif-
ferent brands even in the open markets. 
The insinuation by previous findings that 
some of the drugs circulating in Nigeria are 
of poor quality (Bernard etal., 1999) 
prompted a call for urgent but independent 
laboratory investigation. 
 
The need to select one or more products 
from among several generic drug products 
of the same active ingredients during the 
course of therapy is a cause of concern to 
healthcare practitioner.Therefore, the pre-
sent study was undertaken to evaluate the 
drug sensitivity pattern, minimum inhibitory 
concentration (MIC) and bactericidal activi-
ty of ciprofloxacin brands against common 
clinical isolates encountered in Lagos.  
 
MATERIALS AND METHODS 
Three clinical isolates (Staphylococcus aureus 
Escherichia coli and Salmonella enterica sero-
typeTyphi)and five brands of ciprofloxacin 
hydrochloride tablets (A–Ciprogem; B -
Cenox ;C- Prox ; D - Vitapro and E – Ci-
protab) purchased from retail outlets in 
Akoka area of Lagos State were used. All 
media were autoclaved at 121oC for 15 
minutes after preparation according to man-
ufacturer’s specification and allowed to cool 
before pouring into Petri dishes. All inocula-
tions, plate pouring, serial dilution and so on 
were done under the biosafety cabinet hood 
(BSL 2). Inoculating loop was flamed red hot 
over gas Bunsen burner before and after use. 
 
Morphological and Biochemical Charac-
teristics 
Catalase test: - A loopful of the bacterial 
isolates from the stock culture was taken and 
emulsified with the aid of a wireloop on a 
sterile glass slide. 1 to 2 drops of 3% H2O2 
was added. Effervescence indicated positive 
result (i.e. catalase +ve) and negative if oth-
erwise (Fawole and Oso, 2004). 
 
Coagulase test: A 0.5ml of citrated rabbit 
was added into a test tube, enough colony 
paste was inoculated to make a cloudy sus-
pension and the tubes were incubated at 
35oC for 1-4hours in water bath. Positive 
result was indicated by the presence of 
clumping or agglutination (Fawole and Oso, 
2004). 
 
Starch hydrolysis: Starch agar plates were 
inoculated with different bacterial isolates 
and incubated at 35oC for 2-3 days. At the 
end of the incubation period, each plate was 
flooded with Gram’s iodine and a blue col-
ouration indicates positive result. 
 
Motility test: This test was carried out using 
Edwards and Wigs’ motility medium. The 
semisolid medium was inoculated with the 
different bacteria isolates by stabbing with a 
sterile inoculating needle at the centre of the 
medium column to over half the depth. The 
motile organisms grew and spread out from 
the line of puncture while the non-motile 
organism grew only along the line of punc-
ture (Cowan etal., 1990). 
 
Nitrate reduction test: The test organisms 
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 were inoculated separately into tubes con-
taining nitrate peptone water and Durham 
tubes and incubated at 35oC for 2days. Test 
for nitrate reduction was determined by ad-
dition of 1ml each of reagents 1 and 2 of 
the modified Greiss-illosvay’s reagent. The 
presence of nitrate was indicated by the de-
velopment of a pink, purple or maroon col-
our within a few minutes. Presence of gas in 
the Durham tubes also suggested produc-
tion of gaseous nitrogen and consequently a 
positive result (Cowan etal., 1990). 
 
Sugar fermentation test: Peptone water 
sugar used were prepared as follows; 1.5g of 
peptone water into 100ml of distilled water 
with 5mls of bromothymol sterilized at 
121oC for 15minutes (separate broth for 
each sugar). Also 1g of sugar into 10mls of 
distilled water and sugar solution was steri-
lized by steaming for 30minutes. Aseptical-
ly, the sterile sugar solution and the sterile 
peptone water containing the indicator were 
added together and mixed well. The 5mls of 
the broths was aseptically dispensed into 
sterile test tubes containing an inverted 
Durham tube and corked tightly. 
 
After cooling, each broth test tube contain-
ing Durham tube was inoculated with the 
test organism and a control experiment (an 
un-inoculated test tube) was made at this 
same time. After which all the test tubes 
were incubated aerobically at 37oC for 
24hours. Acid production changed the col-
our of indicator from blue to yellow and gas 
production was shown by the space on top 
of the medium in the inverted Durham tube. 
The broth remains blue for no acid produc-
tion and the Durham tube that was filled up 
indicated no gas production. Tubes with yel-
low colour were recorded as positive to sug-
ar fermentation test while tubes with no col-
our change were recorded as negative to sug-
ar fermentation test. 
 
Uniformity of weight: Using an analytical 
weighing balance, five (5) tablets selected 
from each brand was weighed and the aver-
age weight calculated. In accordance with 
British Pharmacopeia (BP) and United State 
Pharmacopeia (USP), not more than two of 
the individual weights should deviate from 
the average weight by more than the per-
centage given in the pharmacopoeia. The BP 
and USP limits for tablet weight variation for 
tablets over 250 mg should not be more than 
5%.  
23 
Average weight = ∑(x1 + x2 +... xn) 
        N 
Where, x = weight of each tablet; N =total number of tablets. 
% deviation = Weight of tablet – Average weight of tablets x 100 
                                            Weight of tablet 
Determination of Antimicrobial activity: 
The agar cup diffusion technique was used. 
A 0.2ml of logarithmic phase broth culture 
of each bacterium [optical density equiva-
lent to 107-108 cfu/ml (i.e. 0.5 Mac Farland 
standard)] was used to seed sterile molten 
Mueller Hinton agar (MHA) medium main-
tained at 45oC. The seeded plates were al-
lowed to dry in the incubator at 37oC for 
20minutes. A standard cork borer (8mm in 
diameter) was used to cut uniform wells on 
the agar, into which was added 200µl of 
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 25mg/ml, 12.5mg/ml and 6.25mg/ml solu-
tion of each brand. A pre-incubation diffu-
sion of the drugs into the seeded medium 
was allowed for 1hour. Plates were incubat-
ed at 37oC for 24-48 hours after which the 
diameters of the zones of inhibition were 
measured with meter rule (Adeniyi et al., 
1996). 
 
Determination of Minimum Inhibitory 
Concentration (MIC): One tablet equiva-
lent to 500mg of each brand A, B, C, D, 
and E was dissolved in 10mls of sterile dis-
tilled water in a MacCartney bottle to obtain 
a stock concentration of 50mg/ml. Using a 
sterile micropipette, 5000µl (5ml) from each 
stock was aseptically transferred to 5ml of 
sterile distilled water in a sterile bijou bottle 
to half the drug concentration of each stock 
to 25mg/ml, which was the first working 
concentration. Subsequent double fold dilu-
tions were made to give 12.5mg/ml, 
6.25mg/ml, 3.125mg/ml, 1.563mg/ml, 
0.7813mg/ml, 0.391mg/ml, 0.195mg/ml 
until 0.000012mg/ml (0.012µg/ml). The 
agar cup diffusion method (kavanaah, 
1972 ; Adeniyi etal., 1996) was used. A 1.5 
x108cfu (colony forming unit) of overnight 
broth (nutrient, Lab M)  culture of each 
bacterium was inoculated into a molten 
Mueller Hinton agar (Lab M) medium 
maintained at 45oC. The plates were then 
allowed to set and wells were made on them 
using a sterile standard 8mm internal diame-
ter cork borer. Each well was then filled 
with 200µl of every brand concentrations. 
The plates were allowed to stand on the 
bench for about 1hour for diffusion of the 
drug concentrations. The plates were all 
incubated at 37oC for 24hours and read by 
taking note of zone of inhibition measured 
in millimeter (mm). Triplicate plates were 
made for each organism. Control experi-
ment was made for sterility check of the 
agar medium. 
 
Determination of Bactericidal activity 
The bactericidal activity of two brands of 
ciprofloxacin (brand E and D) were deter-
mined in nutrient broth using the viable 
counting technique. (Howard et al., 
1993).The organisms, Salmonella enterica sero-
typeTyphi and Staphylococcus aureus were ex-
posed to increasing concentrations of brand 
D and E, 200µl of logarithmic phase cells 
was inoculated into 5ml quantities of fresh 
warm (37oC) nutrient broth containing the 
antibiotics (4.8ml). The initial viable counts 
were approximately 1.5 x 108 cfu/ml for S. 
aureus and 1.8 x 108 cfu/ml for Salmonella en-
terica serotypeTyphi. An appropriate quantity 
of suspension (0.2ml) was withdrawn and 
transferred aseptically into a McCartney bot-
tle containing 5ml double strength Mueller 
Hinton broth and 4.8ml of the antibiotics 
and thereafter 0.1ml of the whole mixture 
was immediately (at time- 0 mins) transferred 
into a test tube (containing 9.9ml of distilled 
water) thereby obtaining 10-2 dilution. Fur-
ther serial dilutions were made to obtain 10-4 
and 10-6  after which 0.2ml of each dilution 
was plated out using pour plate method at  
different time intervals of 0, 30, 60, 120, 180 
and 240 minutes respectively. Plates were 
then incubated at 37oC for 24-48hours be-
fore counting. The results are expressed as 
percentage (%) viability against time. 
 
RESULTS 
The morphological and biochemical charac-
teristic of a Gram positive (Staphylococcus aure-
us) and Gram negative (Escherichiacoli and Sal-
monellaenterica serotype Typhi) clinical isolates 
used are presented in Table 1. The result of 
weight variation determination of the five 
sampled brands is depicted in Table 2. Negli-
gible variations were observed in the sam-
pled brands with brand D giving the highest 
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 variation of 3.0% which is higher than that 
of other brands but, it still fell within the 
required standard as stipulated in British 
pharmacopeia (2004). All the ciprofloxacin 
brands were very effective against all the 
testedorganisms to varying degree at 25µg/
ml and the mean antibacterial activities of 
all the brands were found to be between 
38.0mm and 44.0mm (Table 3).The Mini-
mum Inhibitory Concentration (MIC) at 
which the five sampled brands of ciproflox-
acin inhibited all the test organisms are pre-
sented in Table 4. Brand E was the most ac-
tive having the least MICs against the test 
organisms except for S. aureus where brand A 
happened to have the least MIC. Based on 
the National Committee for Clinical Labora-
tory Standards (NCCLS, 1994) value for 
MIC of 1μg/ml or less against the three test 
organisms, brand A and E showed better 
result than the rest  
25 
Table 1: Morphological and Biochemical characteristics of the bacteria isolates used 
             Test Staphylococcus aureus Escherichia coli Salmonella enterica 
serotype Typhi 
Gram reaction + - - 
Cellular morphology Cocci Rods Rods 
Growth on MacConkey agar N.D Pink Pale 
Growth on mannitol Yellow N.D N.D 
Catalase test + + + 
Coagulase + N.D N.D 
Oxidase - - - 
Motility - - + 
Citrate + + + 
Indole - + - 
Urease + - - 
Methyl red + - + 
Voges proskaeur - - 0 
Growth on Kligler Iron Agar 
(KIA) slant 
Yellow Yellow Yellow 
Butt Yellow Yellow Yellow 
Hydrogen sulphide production 
(H2S) 
+ - + 
Gas production + + + 
Sugar fermentation glucose A/G A/G A/G 
Lactose A A A/G 
Sucrose A A A/G 
Mannitol A A A 
Maltose A A A/G 
Key: + = growth, - = no growth, A = acid no gas, N.D = Not done, A/G = acid and gas 
J. Nat. Sci. Engr. & Tech. 2016, 15(1): 21-32 
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Table 2: Weight and percentage deviation of tablet from each brand 
 Names  Weight (g)  % deviation 
  
A 0.783 ±0.005  0.1% 
B 0.766 ±0.063  1.3% 
C 0.678 ±0.045  0.9% 
D 0.937 ±0.075  3.0% 
E 0.810 ±0.005  0.1% 
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Table 4:The Minimum Inhibitory Concentration (MIC) of the five brands of  
              ciprofloxacin against the tested organisms (µg/ml) 
Names Staphylococcus aure-
us 
  
 µg/ml 
Escherichia 
coli 
  
 µg/ml 
Salmonella enterica serotypeTyphi 
  
     µg/ml 
A   0.095    0.048 0.19 
B   0.19    0.19 0.38 
C   0.76    0.19 0.38 
D   1.5    0.38 0.38 
E   0.19    0.012 0.024 
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 The percentage survival of S. enterica sero-
type Typhi and S. aureus are shown in two 
brands of ciprofloxacin(Figures 1 and 2) 
(log 10 graphs). From the two graphs, the 
control confirms the effect of the two com-
pared brands against the tested organisms at 
various concentrations (1xMIC, 2xMIC and 
4xMIC) with the 2xMIC and 4xMIC having 
a sharp drop to the zero value as shown 
unlike at 1xMICs. The bactericidal activity 
of each ciprofloxacin against the tested or-
ganisms increased with increase in concen-
trations at 60minutes (Figure 3). 
Figures3 and 4 depicted similar information 
but against S. aureusandSalmonella enterica sero-
type Typhi.  Here, the bactericidal re-
sponse of the two brands differs. The brand 
E at both 2MIC and 4MIC inhibited the pro-
liferation of the test organism (S. aureus) to a 
zero values at 60 minutes. The reverse was 
the case for brand D as shown below; even 
at 4MIC at 60 minutes a significant percent-
age of the test organism still thrives under 
the influence of brand D. This shows that 
brand E is better and more active brand 
compared to brand D. 
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Figure 1: Kinetics of bactericidal studies of two brands of ciprofloxacin against  
               Salmonella enterica serotypeTyphi  
J. Nat. Sci. Engr. & Tech. 2016, 15(1): 21-32 
 28 
Figure 2: Kinetics of bactericidal studies of two brands of ciprofloxacin against  
               S. aureus  
Figure 3: Bactericidal response of Salmonella enterica serotypeTyphi when exposed 
                to increasing concentrations of ciprofloxacin (brand E and D) at 60mins 
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 DISCUSSION 
Among the five different brands of oral for-
mulation of ciprofloxacin sampled, brands 
E and A were the most commonly available 
during the period of the study. Owing to 
their higher demand rate in the market as 
this was confirmed by three out of the four 
visited registered pharmaceutical stores 
from whom those antibiotics were pur-
chased within Akoka area in Lagos State. 
Most (60%) of the sampled brands were 
manufactured in India; these include E, C 
and B while 40% of the brands were manu-
factured in Nigeria namely A and D. Also, 
brand E and A were found to be more ex-
pensive out of all the sampled brands while 
each of the other three brands were halve 
the price of E and A. They were all available 
as 500mg per tablet caplet and were within 
their shelf live period at the time of the in-
vestigation. All the samples had batch num-
ber, NAFDAC registered number. The im-
portance of NAFDAC certification of a par-
ticular antimicrobial agent cannot be over 
emphasized as researched work (Mukhtar 
etal., 2009) carried out on six brands of 
ciprofloxacin against four clinical isolates 
showed that five (certified) of the brands 
were of good and standard quality while one 
of them which was not certified by 
NAFDAC (without NAFDAC registration 
number) proved to be of a very low quality. 
 
The uniformity of weight assay for drug 
products with the strength 500 mg (film 
coated tablets), a ±5% of the average pass 
the test for uniformity of weight. The results, 
thus, indicate that all the sampled products 
possess acceptable uniformity of weight 
within the pharmacopoeia limit. Though, 
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Figure 4: Bactericidal response of S. aureus when exposed to increasing concentra-
tions of ciprofloxacin (brand E and D) at 60mins 
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 brand D has the highest detected variation 
in weight (3%) compared to its counterparts 
nevertheless, it still fell within the range lim-
it. 
 
In the mean antibacterial activity or suscep-
tibility testing of the formulations against 
the test organisms,the drugs appeared with 
appreciable effects, but the drugs were of 
different manufacturers and so there are 
possibilities of difference in properties but 
may not be tangible enough to deviate from 
the required limit. Brand D shows the least 
diameter zone of inhibition of 38.0 mm on 
Escherichia coli at 25µg/ml indicating a good 
activity as the others. The brands displayed 
very similar potencies at higher concentra-
tions but towards the least concentrations 
distinguished themselves. In terms of the 
minimum inhibitory concentration, brand A 
and E presented the least MIC against 
Staphylococcus aureus and E. coli with 0.095μg/
ml, 0.048μg/ml and 0.19μg/ml, 0.012μg/ml 
for the respective brands against the test 
organisms and this fell within the required 
range specified in NCCLS; in vitro MIC val-
ue of ≤1μg/ml range, (NCCLS, 1994). The 
activity of all the sampled brands against 
Salmonella enterica serotypetyphi (etiological 
agent of typhoid fever) in terms of the 
MICs is somewhat appreciable.  
 
Comparatively, brands, E and D showed 
the most and “least” effective bactericidal 
action respectively. As the concentration 
dependent antibiotics they are, both of 
them were very active against the tested or-
ganisms (S. aureus and Salmonella enterica sero-
type typhi) at higher MICs during the stipulat-
ed time interval of the experiment com-
pared to lower MIC (1xMIC). The growth 
of the test organisms reduced gradually and 
drastically as the concentration of the sam-
pled brands increases from 1xMIC, 2xMIC 
to 4xMIC.  From the results obtained, brand 
E kills faster than its D counterpart. There 
was an observable difference in the viable 
organisms at 1xMIC, 2xMIC and 4xMIC of 
brand E and D. The kinetic responses of 
both Salmonella enterica serotypetyphi (G-ve) 
and S. aureus (G+ve)against brand D and E 
at 60 minutes at the various MICs shows 
that Brand E has a lesser number of test or-
ganisms thriving under its influence com-
pared to brand D. This however makes 
brand E a better and more active compared 
to brand D. The results obtained showed 
that ciprofloxacins are more effective against 
Salmonella enterica serotypetyphithan S. aureus 
and therefore conforms to the findings by 
Bennet and Brown (2003) that ciprofloxacins 
are very effective but particularly against 
Gram-negative than Gram-positives. The 
reasons for the results above maybe due to 
the nature (structure) of Gram-negative or-
ganisms (e.g. Salmonella enterica serotypetyphi) 
cell wall which is very complex but made up 
of a thin peptidoglycan  layer (2-7nm) com-
pared to that of Gram-positive organisms 
which is very thick (20-80nm) (Willey et al., 
2008). Research has shown that ciprofloxa-
cin is the 5th most prescribed antibiotics and 
is commonly used for the treatment of uri-
nary and intestinal infections and was once 
considered a powerful antibiotic of last re-
sort (Brunton et al., 2005).  
 
In conclusion, the insinuation that some of 
the drugs circulating in Nigeria are of poor 
quality prompted a call for urgent but inde-
pendent laboratory investigation of some of 
the widely consumed antibiotics in Lagos 
state.The in vitro analysis revealed that there 
is no significant difference in the results for 
different brands and from the result ob-
tained, the antibacterial activities of all the 
sampled brands are within the acceptable 
limit making them drugs of choice in this 
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 order (E>A>C>B>D).  Therefore the sam-
pled brands of ciprofloxacin oral formula-
tions that were tested showed acceptable 
quality against the indicated susceptible or-
ganisms. 
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